|
Jan 9
|
Sarepta (SRPT) Rises on Solid Q4 and 2023 Preliminary Results
|
|
Jan 9
|
Vericel Corporation (VCEL) Moves 7.0% Higher: Will This Strength Last?
|
|
Jan 9
|
2 Growth Stocks That Could Make You Richer in 2024 and Beyond
|
|
Jan 5
|
Allogene (ALLO) Down 20% on Strategic Changes in Pipeline
|
|
Jan 5
|
3 Top Biotech Stocks Worth Adding to Your Portfolio in 2024
|
|
Jan 4
|
Esperion (ESPR) Settles Milestone Dispute With Daiichi Sankyo
|
|
Jan 4
|
Wall Street Analysts Believe Sarepta Therapeutics (SRPT) Could Rally 50.54%: Here's is How to Trade
|
|
Jan 3
|
Why Moderna (MRNA) Stock Price Was Up 13% on Tuesday
|
|
Jan 3
|
Best Momentum Stocks to Buy for January 3rd
|
|
Jan 2
|
Sarepta Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
|
|
Dec 29
|
Sarepta (SRPT): Strong Industry, Solid Earnings Estimate Revisions
|
|
Dec 28
|
3 Things About Sarepta Therapeutics Every Smart Investor Knows
|
|
Dec 27
|
15 Best Fast Growth Stocks to Buy Now
|
|
Dec 26
|
13 High Growth Healthcare Stocks to Buy
|
|
Dec 26
|
Fluor Corporation and Align Technology have been highlighted as Zacks Bull and Bear of the Day
|
|
Dec 22
|
Sarepta Therapeutics Seen Expanding Duchenne Treatment Label
|
|
Dec 22
|
Could Sarepta Therapeutics Be the Next Vertex Pharmaceuticals Stock?
|
|
Dec 22
|
3 Beaten-Down Biotech Stocks to Buy for a Turnaround in 2024
|
|
Dec 22
|
Sarepta Therapeutics Submits Efficacy Supplement to Expand the ELEVIDYS Label to include Duchenne Muscular Dystrophy Patients without Restriction to Age or Ambulatory Status
|
|
Dec 22
|
Sarepta tests FDA flexibility with bid to expand Duchenne gene therapy’s approval
|